Clonal plasma cell proliferation that is immunophenotypically and cytologically identical to plasma cell myeloma, but manifests as localized disease
Diagnostic Criteria
Osseous plasmacytoma/solitary plasmacytoma of bone
Solitary lytic bone lesion consisting of clonal plasma cells
No evidence of plasmacytosis in other bone marrow sites or clinical features of plasma cell myeloma (renal insufficiency/ anemia/ hypercalcemia/ additional lesions on skeletal survey)
Extraosseous plasmacytoma
Extraosseous/extramedullary mass of neoplastic plasma cells
No evidence of plasmacytosis in other bone marrow sites or clinical features of plasma cell myeloma (renal insufficiency/ anemia/ hypercalcemia/ additional lesions on skeletal survey)
Dita Gratzinger MD PhD
Department of Pathology
Stanford University School of Medicine
Stanford CA 94305-5342
Initial posting/updates : 9/1/07, 4/15/10
Supplemental studies
Flow cytometry or immunohistochemical studies to establish plasma cell differentiation and light chain monoclonality, as for plasma cell myeloma
Hematolymphoid markers
CD45 absent or dim in >99%
B cell and plasma cell markers
CD138 >99%
CD38 >99%
CD79a, most
CD20 variable, often absent
CD19 variable, often absent
CD56 up to 80% -- aberrant antigen
Cytoplasmic kappa or lambda light chain by flow cytometry, in situ hybridization, or immunohistochemistry
Useful Laboratory Tests
Serum or urine protein electrophoresis, immunofixation, light chain quantification
Quantitation and typing of monoclonal immunoglobulin / light chain
Serum free light chain analysis may be required to demonstrate clonal light chains
These studies may be used to
Establish presence of a monoclonal plasma cell population
Quantitation helps subtype the plasma cell dyscrasia (i.e. >3g/dL serum monoclonal protein is a major criterion for myeloma)
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW . WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, International Agency for Research on Cancer, Lyon, 2008
Warnke RA, Weiss LM, Chan JKC, Cleary ML, Dorfman RF . Tumors of the Lymph Nodes and Spleen, Atlas of Tumor Pathology, AFIP Third Series, Fascicle 14, 1995
Chang ST, Liao YL, Lu CL, Chuang SS, Li CY. Plasmablastic cytomorphologic features in plasma cell neoplasms in immunocompetent patients are significantly associated with EBV. Am J Clin Pathol. 2007 Aug;128(2):339-44.
Greipp PR, Leong T, Bennett JM, Gaillard JP, Klein B, Stewart JA, Oken MM, Kay NE, Van Ness B, Kyle RA. Plasmablastic morphology--an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group. Blood. 1998 Apr 1;91(7):2501-7
Martin W, Abraham R, Shanafelt T, Clark RJ, Bone N, Geyer SM, Katzmann JA, Bradwell A, Kay NE, Witzig TE. Serum-free light chain-a new biomarker for patients with B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. Transl Res. 2007 Apr;149(4):231-5.
Raja KR, Kovarova L, Hajek R.Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders. Br J Haematol. 2010 Mar 1. [Epub ahead of print]
Van Camp B, Durie BG, Spier C, De Waele M, Van Riet I, Vela E, Frutiger Y, Richter L, Grogan TM. Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56. Blood. 1990 Jul 15;76(2):377-82.